Whether enhanced antitumor CD8+ T cell immunity was mediated by direct and/or cross-presentation of the TAP downregulation-induced antigens by the tumor cells themselves or by tumor-resident APC, respectively, remains to be determined. The gene discussed is CD8A; the disease is neoplasm.